swiss pharma companies

SWISS COMPANIESAcino Pharma

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops and manufactures generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents.

Members of Group Management      Peter Burema, CEO      Robert Schmid, CFO      Dr. Harald Haubitz, Head Production & SCM      Dr. Jean-Daniel Bonny, Head of Research & Development Phone +41 61 338 60 91. Fax +41 61 338 60 82 jean-daniel.bonny(at)acino-pharma.com      Jörg Gebhardt, Head IT & HR      Daniel Hossli, Head Group Legal (from November 1, 2011)      Ruud van Anraat, Chief Commercial Officer      Dr. Ulf-Hergen Westphal, Head Quality

Chairman of the Board of Directors      Luzi Andreas von Bidder

Members of the Board of Directors       Hans Peter Hasler, Vice-Chairman      Dr. Anders Härfstrand      Jürg Michel      Dr. René Muttenzer      Dr. Andreas Rummelt

Honorary ChairmanDr. Hans-Peter Schär

PhonePhone +41 61 338 60 00Fax     +41 61 338 60 80info(at)acino-pharma.com

Acino Holding Ltd.Basle +41 61 338 60 00

Acino Pharma Ltd.Basle +41 61 338 60 00

Acino Pharma Ltd. Liesberg+41 61 775 80 00

Acino Pharma Ltd.Aesch +41 61 756 40 00

Acino Supply Ltd.Aesch +41 61 756 40 00

Acino AGMiesbach Phone +49 8025 2867-0

Acino Pharma, Inc.USA +1 (215) 345 7397

Actelion Pharmaceuticals LtdPhone: +41 61 565 65 65Fax: +41 61 565 65 00

BOARD OF DIRECTORS

Jean-Pierre Garnier Robert Cawthorn

Juhani Anttila Robert J. Bertolini

Jean-Paul Clozel Carl Feldbaum

Werner Henrich Michael Jacobi

Armin Kessler Jean Malo

Andrew J. Oakley, Chief Financial Officer

Phone: +41 61 565 65 65Fax: +41 61 565 65 00

Bachem is specialized in the process development and the manufacturing of biologically active peptides and complex organic molecules as active pharmaceutical ingredients (APIs) and as innovative biochemicals for research purposes.

Dr. Thomas FrühExecutive Vice President and COOBachem AG, Switzerland

Dr. Rolf Nyfeler, Chief Executive Officer (CEO)Stephan Schindler, Chief Financial Officer (CFO)Dr. Lester Mills, Chief Marketing Officer (CMO)Dr. Daniel Erne, Chief Technology Officer (CTO) 

Switzerland HQTel +41 61 935 2323/33Fax +41 61 935 2325

Peptide research and development+41 61 935 2333

Development and manufacturing of active pharmaceutical ingredients (API)+41 24 482 4444

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Its fully integrated research and development operations are currently focused on antibiotics and antifungals, as well as on the development of dermatology and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options in the hospital and specialty care setting

Management Committee

Dr. Anthony Man Dr. IngridHeinze-Krauss Prof. Achim KaufholdDr. Laurenz Kellenberger Mr. Hans Christian Rohde Mr. Ronald Scott

Basilea Pharmaceutica Ltd.Grenzacherstrasse 487PO Box4005 BaselSwitzerlandT: +41 61 606 11 11F: +41 61 606 11 12email: info_basilea@basilea.com

Beiersdorf AG

Focus on Skin Care. Closer to Markets. These two elements form Beiersdorf’s consumer business strategy. Skin care is our key competence since 130 years and also today the focus of all our efforts. With closeness to the markets we are able to identify local consumer wishes quickly and align ourselves precisely with the respective market development.

Dr. Walter Diembeck, HamburgResearch chemist, Beiersdorf AG

Telephone: +49 (40) 4909-0Fax: +49 (40) 4909-3434

Switzerland +41-61-415 6111 +41-61-415 6332

Laboratoires La Prairie SA +41-44-9478282 +41-44-9478180

BÜHLMANN Laboratories AG SwitzerlandFon: +41 61 487 12 12Fax: +41 61 487 12 34info@buhlmannlabs.ch

CARBOGEN AMCIS is a leading provider of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. The integrated services of CARBOGEN AMCIS provide innovative, timely and safe drug development solutions that allow customers to make the best use of their available resources.

Sales Manager EuropeDr Thomas Schlatterer (+41) 628-89 36 42Fax: (+41) 628-89 36 10 Mobile: (+41) 795-93 26 48

UK and Scandinavia Sonal Naik Tel: Fax: (+41) 619-35 53 00 Mobile: (+44) 752-596 55 30

France, Belgium, Southern Europe and Middle EastJocelyn Saget Tel: (+33) 241-69 26 83Fax: (+33) 241-69 26 83 Mobile: (+33) 672-59 35 03

Central Europe NorthDr Alexander Strätz Tel: (+49) 2207-70 17 97Fax: (+49) 2207-919 91 93 Mobile: (+49) 162-426 24 35

Pascal Villemagne as vice president commercialMark Griffiths, CEO

HQ SwitzerlandTel: (+41) 61-935 53 53Fax: (+41) 61-935 53 00

Dishman is a global, dynamic group of companies offering a continuum of services to the pharmaceutical industry. We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services.

Jay. R. Vyas, Managing Director

Dr Denish Shah GENERAL MANAGER R&DDr Rajiv Desai PRESIDENT QUALITY

Custom Services DirectorChristian DowdeswellTel: +44 (0)17 4473 0867Fax: +44 (0)17 4445 1141christian.dowdeswell@dishmangroup.com

Sales Manager (Central & Eastern Europe)Michael ExnerTel: +49 176 2072 1806 Fax: +44 207 323 0609michael.exner@dishmangroup.com

Sales Manager (Western Europe)Jean-Pierre Onckelet Tel: +33 1 48 61 95 14Fax: +44 207 323 0609jean-pierre.onckelet@dishmangroup.com

Manufacturing SitesIndia

Ahmedabad IndiaTel.: +91 2717 302400Fax: +91 2717 302499dishman@dishmangroup.com

Dishman Pharmaceuticals and Chemicals Ltd.Ahmedabad, IndiaTel: +91 (0)79 2282 0103Fax: +91 (0)79 22821633dishman@dishmangroup.com

China ShanghaiDishman Pharmaceuticals and Chemicals (Shanghai) Co., Ltd.Tel: +86 21 6712 1166Fax: +86 21 6712 0811sales@dishman.net.cn

NetherlandsDishman Netherlands B.V.Tel: +31 (0)318 545 754Fax: +31 (0)318 529 374info@dishman-netherlands.com

CARBOGEN AMCISHead Office Tel: (+41) 61-935 53 53Fax: (+41) 61-935 53 00info@carbogen-amcis.com

Aarau SwitzerlandTel: (+41) 62-836 48 00Fax: (+41) 62-836 48 10

Neuland SwitzerlandTel: (+41) 62-889 36 00Fax: (+41) 62-889 36 10

United KingdomTel: (+44) 161-223 33 44Fax: (+44) 161-220 87 78

CIS Pharma is a pharmaceutical research company specialised in drug delivery. We develop novel treatments in the fields of ophthalmology and dermatology. We are innovators patenting New Chemical Entities, Drug Delivery Systems and Medical Devices with a strong scientific and commercial rationale.

Christoph Schäfer, CEO

Doris Schäfer, CFO

Hans Hitz, R & D

Rolf Schäfer, Corporate Strategy and Innovation

Tel: +41 61 935 53 23Fax: +41 61 931 27 17Christoph.Schaefer@cis-pharma.com

Evolva Pharmaceuticals

Our emphasis is on small-molecule compounds that can be delivered orally.

EV-077 for the treatment of complications of diabetesEV-077 & EV-075 for the treatment of viral infectionsEV-021 for the treatment of bacterial infectionsEV-009 for the treatment of bacterial infectionsEV-086 for the treatment of fungal infections

Neil Goldsmith CEO and Managing DirectorDr. Alexandra Santana Sorensen PresidentJakob Dynnes Hansen, MBA Chief Financial OfficerProf. Dr. Jutta Heim Chief Scientific OfficerDr. Norbert Bender Chief Medical OfficerDr. Panchapagesa Murali Managing Director & CEO, Evolva IndiaDr. Pascal Longchamp Chief Business OfficerDr. Simon Waddington CEO, Evolva Nutrition Inc.

Isabelle StöcklinPA to the CEO isabelles@evolva.com+41 61 485 2006

Tel: +41 61 485 2000fax: +41 61 485 2001

GABA International AG is a European branded manufacturer of innovative, top-quality oral care products. GABA has been collaborating closely with dental professionals for over 50 years.

Ms. Christiane SpiegelhalderHead of Scientific Affairs Department

SwitzerlandPhone +41 61 415 60 60Fax +41 61 415 60 00

Midatech LtdMidatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self assembling biocompatible nanoparticle technology.

Professor Thomas Rademacher Chairman and CEOStorme Moore-ThornicroftVice President, Corporate ManagementT: +44 1235 528 022

The company’s corporate capabilities are further supported by the following wholly owned subsidiaries: Midatech US, Pharmida AG and Midatech Biogune S.L.

Business Development, Partnering and LicensingEurope Peter Sorg T: + 41 797 079 464

Midatech US Sterling Johnson PresidentT: +1 760 936 1024

Drug Development Pharmida AGJan Mous CEO T: + 41 793 522 314

cGMP Manufacturing and ResearchMidatech Biogune S.L.Justin Barry CEO T: + 34 944 034 020

HQ +44 1235 528 022 F: + 44 1235 528 023

Genedata transforms data into intelligence with innovative software solutions that support large-scale, experimental processes in life science research. Founded in 1997, Genedata delivers enterprise solutions for data analytics that streamline R&D workflows and improve research productivity

Dr. Othmar Pfannes CEODr. Hans Peter Fischer Head of Genedata Phylosopher® Business UnitDr. Stephan Heyse Head of Genedata Screener® Business UnitDr. Jens Hoefkens Head of Genedata Expressionist® Business UnitDr. Kurt Zingler Managing Director – USADr. Peter Haberl Managing Director – GermanyHideki Shimohiro Managing Director – Japan

SwitzerlandTel: +41 61 511 8400Fax: +41 61 511 8484

GermanyTel: +49 89 4581 9010Fax: +49 89 4581 9015

Karger a Life sciences Publishing agency devoted to printing books for sciences

Congress announcements, invitations to exhibitionsExhibition CoordinatorMonika Willin (m.willin@karger.ch)

+41 61 306 11 11 (switchboard)

BioResearchLonza comprises the areas of Cell and Molecular Biology, Drug Discovery and applied research as well as quality control laboratory testing systems including tools for quality control tests for microbial detection.

Stefan Borgas CEO

General Contacts for Lonza Custom ManufacturingHQTel +41 61 316 81 11Fax +41 61 316 91 11

Uwe H. Böhlke Member of boardToralf Haag Member of Board

North AmericaTel +1 201 316 9200custom@lonza.com

Europe & Rest Of WorldTel +41 61 316 8111custom@lonza.com\

MEPHA PHARMA AGAnti-allergicsAcne, antimycoticsAnti-infectives, anti-malarialsAnti-diarrhoeals, anti-ulcer

Dr. Jürgen BetzingSenior Director Tech Ops Generics Europe

Dr. Victor BrantlVice President Generics Development Europe

Tel: +41 (0) 61 705 43 43 Fax +41 (0) 61 705 43 85

Mondobiotech is an unconventional drug discovery company dedicated to treating rare and neglected diseases, some of them chronic, many of the them life-threatening.Mondobiotech (SIX Swiss Exchange RARE) is a Swiss research company focused on finding treatments for rare and neglected diseases.

Paolo Bassanini, Investor & External Relations

Ruggero Gramatica CEO and Board MemberDr. habil. Dorian Bevec CSO and FounderPaolo Barbieri CFOMaria Teresa D'Antonangelo Bühlmann Corporate Affairs & Business SupportDavid Cox Head of BD&L

Tel +41 (0)840 20 00 10Fax: +41 (0)840 20 00 11

Novartis

Stefan HartmannHead Clinical Operation Managertherapeutic area of Immunology and Infectious Diseases

Joseph Jimenez,Chief Executive Officer of Novartis AG

Dr. Jürgen Geiger BrokatzkyHead of Human Resources

David Epstein,Division Head, Novartis Pharmaceuticals

Armin J. ZustHead of Novartis Switzerland

Dr. Dr. OswaldDivision Head, Novartis Vaccines and Diagnostics

Novartis International AGBasel Switzerland Phone +41 61 324 11 11 Fax +41 61 324 80 01

ABAC R&D Ltd.

ABAC is interested in complementary partnerships for product development, manufacturing, marketing and distribution.

Contact person Dr. Othmar Kaeppeli, Executive DirectorCompany main phone +41 (43) 888 50 50Company main fax +41 (43) 888 50 12Website www.abac.ch

PENTAPHARM has a long-standing tradition as an innovative and reliable supplier of active ingredients for the pharmaceutical, diagnostic and cosmetic industry. Our roots as researchers, developers and manufacturers of state-of-the-art products reach back to 1948.

PENTAPHARM develops and manufactures reagents and test systems for coagulation and fibrinolysis diagnostics.

DSM Nutritional Products AG Phone: +41 61 706 4848Fax: +41 61 706 4800

Beat Ineichen Director Sales & Marketing PharmaTelefon: +41 706 46 77

Christine Spaenhauer-Horanyi Senior Product ManagerTelefon: + 41 61 706 46 48

Hans van Leeuwen General ManagerTelefon: +41 61 706 48 32

Matthias Henz Head QM & Regulatory AffairsTelefon: +41 61 706 47 77

Christian Witzig Head of OperationsTelefon: +41 61 706 47 51

Thierry Ketterlin Chief Financial Officer Telefon: +41 61 706 46 60

Abel Ferrandez Head of R&DTelefon: +41 61 706 48 84

Renata Putnik Head Human ResourcesTelefon: +41 61 706 46 66

Daniela Tschanz Management Assistant+41 61 706 48 32

Christian H. Lutz, Chairman of the Board

The Permamed I founded in 1979. We are now a separate and independent Swiss pharmaceutical company in Switzerland and employs around 60 staff in the development, manufacture, licensing, marketing, and consulting for physicians in practice and clinic as well as in pharmacies and drugstores.

Tobias Lutz Business dev. manager

Peter Bönzli COO Board Member

Dr. Peter Huber, Board MemberMedical and Scientific Director and Head of Galenic development

Allemann, Peter Head of Production

Areas of expertise:

Production and PlanningPackagingPurchase of raw materials

Permamed AGT +41 (0) 61 725 20 20F +41 (0) 61 725 20 40

permamed(at)permamed.ch

Polyphor is a Swiss research-driven pharmaceutical company developing innovative products with high therapeutic benefit to the patient and providing high quality support to its industry partners engaged in drug discovery.

Executive Committee

Jean-Pierre Obrecht CEO

Daniel Obrecht CSO

Christoph Rentsch CFO

Michael Altorfer Head Corporate Development, Deputy CEO

Klaus Dembowsky Head Drug Discovery & DevelopmentChief Medical Officer

Marc Thommen Head Technology Platforms

Peter Zbinden Head Internal Services

Polyphor LtdHegenheimermattweg 125 CH-4123 Allschwil Switzerland Tel. +41 61 567 16 00 Fax +41 61 567 16 01 info@polyphor.com

Proreo Pharma is a privately owned Swiss based specialty pharmaceutical company.With emphasis on the therapeutic areas of central nervous system, gastroenterology, renal care, and surgery, Proreo Pharma focuses on the acquisition, development, and commercialization of innovative specialist medicines.In Switzerland, France and Germany, the company uses its own commercial infrastructure to market its products. Further presence and reach is achieved via a network of distribution partners.

Rudolf Syz - Founder & ChairmanSwitzrlandGünter Graubach - Founder & Chief Executive Office GERMANY

Dr. Roland Rutschmann - Commercial Director FRANCE

Dr. Andreas von Sprecher - Research & Development Director

Marius Raulf - Managing Director, Proreo Pharma Germany

Sharon Uval Maran - Chief Executive Officer, Prospera Pharma Ltd (Cyprus)

Phone: +41 61 927 8777Fax: +41 61 927 8775

Phone: +33 1 42 35 72 80Fax: +33 1 42 35 45 77

Phone: +49 2102 1016790Fax: +49 2102 1016791

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.

Thomas Meier is Chief Executive OfficerKlaus Schollmeier, ChairmanMartin Gertsch is Chairman

Prof. Katharine M. D. Bushby received her doctorate in medicineDr. Timothy J. Rink is chairman of the strategy panel (board of directors)Prof. Markus A. Rüegg is Professor for Neurobiology

Günter MetzVP Operations & Alliance Managementphone: +41 (0)61 906 89 13guenter.metz@santhera.com

Thomas StaffelbachVP Head Public & Investor Relationsphone: +41 (0) 61 906 89 47

Thomas StaffelbachVP Head Public & Investor Relationsphone: +41 (0) 61 906 89 47

HQ+41 (0)61 906 89 50

Company Subsidiaries

Switzerlandphone: +41 (0)61 906 89 50

United States of Americaphone: +1 617 886 51 61

Germanyphone: +49 7621 1690 200

Canadaphone: +1 514 448 5186

S.L.A. Pharma is a privately owned company, located outside Basel in Switzerland with an operations arm in the UK. Our dedicated team includes experienced pharmaceutical, medical and regulatory professionals with the required knowledge and expertise to drive the product from conception through to launch.

Therapeutic AreasFAP is a genetically inherited condition, which presents as large numbers (maybe hundreds) of polyps in the large intestine...

Perianal Crohn's disease is an inflammatory condition that affects the anus and perianal area and is considered to be one of the most

Head Office

S.L.A. Pharma AGSwitzerland

T / +41 61 922 05 11F / +41 61 922 06 33

+44 (0)1923 681001F / +44 (0)1923 681221

Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (Parkinson's disease, Alzheimer's disease and other cognitive disorders, bipolar disorder, and alcohol and drug dependence)

Timo Veromaa President & CEOIan Massey COOChris Piggott Chief business OfficerZack McNealy Interim CFOStephen Bandak CMO

FinlandTel. +358 2 274 89 00 Fax +358 2 274 89 10

Switzerland Tel: +41 61 206 9202 Fax: +41 61 206 9201

Tel: +1 650-244-4850 Fax: +1 650-244-4874

Vivendy Therapeutics Ltd. was founded in March 2006, as a spin-off of Inotech Biotechnologies AG. The company's mission is the development of an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS IVA), a rare lysosomal storage disease (LSD)

Executive Director Dr.Gosse Bruinsma

Director Clinical and Regulatory Affairs Dr. Gertrud Thormann-Huber

Medical Director Professor Dr. Arndt Rolfs

Technical Director Dr. Hans Paul Walliser

CFO Dr. Florian Fischer

Chairman Dr. Gerhard Ries; General Partner, BioMedInvest AG, Basel; Switzerland Members of the Board of DirectorsDr. Annegret de Baey-Diepolder; Partner, TVM Capital, Munich; GermanyDr. Jörg Neerman; Partner, LSP, Life Sciences Partners; Munich; GermanyDr. Domenico Valerio; Partner; AESCAP Venture Management BV, Amsterdam, NetherlandsProf. Dr. Walter Dettling; Chairman of the Board of Directors Inotech Biotechnologies Ltd., Basel, Switzerland

Vivendy Therapeutics Ltd.SwitzerlandTel: +41-61-271 87 80Fax: +41-61-271 87 81web: www.vivendy.chmail: info[at]vivendy.ch

Xenometrix produces and distributes today's most advanced Ames mutagenicity assays (microfluctuation assays) and cytotoxicity screening kits designed to reduce the amount of test compound, hands-on time and consumables.The Ames II / Ames MPF Microfluctuation Assays are all modifications of the traditional Ames plate incorporation assay.

Nicole Weiland-Jäggi, PhD in Biochemistry, CEO Jens Germer, PhD in Microbiology. Marketing and Sales International Sini Flückiger, PhD in Biochemistry. Production, Development, Quality Assurance, Ames II, Ames MPF®, In Cytotox Product Range, umuC. Markus Kamber, PhD in Cell Biology and Immunology. Production, Development, Quality Assurance, Technical Support In Cytotox Product Range, Ames II, Ames MPF® and umuC. Nicole Gahler, Logistics and Orders

Chris Wessner, Administration

Hans Jürgen Schmidt, Marketing and Sales for Switzerland, Germany, Austria, Israel, Middle East

Xenometrix AGSwitzerlandTel. +41 61 482 14 34Fax +41 61 482 20 72info@xenometrix.ch

As an International Contract Research Organisation (CRO), Swiss Pharma Contract Ltd. Offers a Variety of Services Focused on Clinical Pharmacology and Clinical Research, Ranging from First Testing of a New Drug in Man to Post-Marketing Clinical Studies.

Rolf Pokorny, M.D., M.Sc. Head of Clinical Research / Biometrics

Michael Seiberling, M.D. Head of Clinical Pharmacology

Thierry Kamtchoua, M.D. Head of Clinics

Aline Cossy-Gantner, Business Development Director

Swiss Pharma Contract Ltd.

SwitzerlandTel +41 / 61 / 487 24 00,Fax +41 / 61 / 487 24 01